New drug combo vs standard for HER2+ advanced breast cancer
Treatments studied
Part of Cancer clinical trials.
This trial compares two drug combinations for HER2-positive breast cancer that has spread. It tests a newer drug (Disitamab Vedotin + Pyrotinib) against a standard treatment (THP) as a first treatment option.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are a woman aged 18 to 75 with breast cancer that has spread to other parts of the body.
- Your cancer must be HER2-positive, meaning it has a specific protein on its surface.
- You have not had chemotherapy for breast cancer that has spread (first-line treatment).
- You have at least one tumor that can be measured on a scan.
- You are not pregnant or breastfeeding and agree to use effective birth control during the study.
- Your liver, kidney, and heart function are within certain limits as checked by routine blood tests.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 3 trial tests disitamab vedotin (a targeted drug) in people with hormone receptor–positive, HER2-low metastatic breast cancer that can’t be cured with surgery or radiation. It aims to see whether the drug can control the cancer better than current standard care.
This trial tests different combinations of the drug Inetetamab as a first treatment for breast cancer that has spread and is HER2-positive. It aims to find which combo works best and is safe for newly diagnosed metastatic patients.
This trial tests a combination of two targeted drugs (Disitamab Vedotin and Pyrotinib) for people with HER2-positive early breast cancer. It aims to see if this treatment can improve outcomes before standard therapy.
This trial tests a new combination of targeted drugs (Disitamab Vedotin and RC148) against a standard chemotherapy (Abraxane) with or without an immunotherapy drug (Toripalimab) for advanced breast cancer that is HER2-low and hormone receptor-negative. The goal is to see if the new combination works better at shrinking tumors and slowing cancer growth.
This trial tests a new drug called RC48 combined with chemotherapy for people with HER2-positive advanced breast cancer that has worsened after treatment with a specific type of antibody-drug conjugate (a drug that targets cancer cells). The goal is to see if this new combination can help when other treatments have stopped working.
This trial tests a new combination of drugs (DV plus pertuzumab, with or without toripalimab) given before surgery for HER2-positive breast cancer. The goal is to see if this treatment can shrink the tumor and improve outcomes.
Hear when a new HER2-positive Metastatic Breast Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.